Pascolizumab Explained

Pascolizumab is a humanized monoclonal antibody for the treatment of asthma.[1] A Phase II clinical trial in patients with symptomatic glucocorticoid naive asthma was conducted in 2001/2002. Development was discontinued as it showed little benefit.[2]

Notes and References

  1. Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, Cook RM . Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma . Clinical and Experimental Immunology . 130 . 1 . 93–100 . October 2002 . 12296858 . 1906490 . 10.1046/j.1365-2249.2002.01973.x .
  2. Bice JB, Leechawengwongs E, Montanaro A. Biologic targeted therapy in allergic asthma. Annals of Allergy, Asthma & Immunology. 112 . 2 . 108 - 115. 2014 . 10.1016/j.anai.2013.12.013.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pascolizumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.